What is the latest published BRO stock rating?

Brown & Brown, Inc. is shown with Buy in the latest published report, analyzed 2026-10-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BRO analysis?

The full latest published report, analyzed 2026-10-08, lives at /stocks/BRO/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for BRO?

The latest published report analyzed 2026-10-08 gives BRO a fair value of USD 82 and a potential value of USD 110. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the BRO page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BRO Stock: Fundamentals & Analysis | StockMarketAgent.AI

Zaloguj się Start free

Brown & Brown, Inc. (BRO)

NYSE: BRO · USD

—

StockMarketAgent Research · Analyzed 2026-10-08

Our latest published analysis: BRO rated Buy

Brown & Brown, Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$82.4 / share

Potential value

$110 / share

Upside to FV

+32.9%

Moat

7.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$20.8B
P/E (forward)	12.6x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 12.6x
Market cap: $20.8B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$3.05B	$3.57B	$4.26B	$4.81B	$5.90B	+17.9%
Gross profit	$1.41B	$1.76B	$1.42B	$2.30B	$2.83B	+19.0%
Operating income	$919.7M	$1.05B	$1.28B	$1.50B	$1.62B	+15.1%
Net income	$587.1M	$672.0M	$871.0M	$993.0M	$1.05B	+15.8%
EPS (diluted)	$2.07	$2.37	$3.05	$3.46	$3.16	+11.2%
EBITDA	$1.01B	$1.16B	$1.15B	$1.73B	$1.98B	+18.3%
R&D	$0	$0	$0	—	—	+3.9%
SG&A	$2.08B	$1.82B	$2.19B	$2.41B	$2.94B	+9.0%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ACGL	Arch Capital Group Ltd.	—	—	—	—	—	—	Zdecydowanie kupuj
AIG	American International Group Inc.	—	—	—	—	—	—	Zdecydowanie kupuj
AIZ	Assurant, Inc.	—	—	—	—	—	—	Trzymaj
AJG	Arthur J. Gallagher & Co.	—	—	—	—	—	—	Kupuj
ALL	The Allstate Corporation	—	—	—	—	—	—	Zdecydowanie kupuj
AMP	Ameriprise Financial, Inc.	—	—	—	—	—	—	Kupuj

Base and Bull scenarios

Base60%

Price target

$82.40

+32.9% from spot

The Base case represents the modal operating path, where performance aligns with management guidance and sell-side consensus estimates. Consolidated revenue reaches $6,985,067,150 in FY2026, reflecting the contribution of $1.7B to $1.8B from Accession and organic growth within guided bands of 1.5% to 2.5% in Retail and 2% to 4% in Specialty Distribution. Operating margins remain structurally superior to peers in FY2026, supported by ~35% Specialty Distribution profitability and reaffirmed synergy realization of $30M to $40M. Asset-light operations ($68M capex in FY2025) produce strong operational cash flows of $1.35B+, facilitating steady deleveraging.

Consolidated revenue tracks consensus estimates to $6,985,067,150 in FY2026 and $7,286,172,630 in FY2027
Diluted EPS meets consensus at $4.48 for FY2026 and $4.81 for FY2027
Consolidated operating margin remains steady in FY2026, gradually expanding through FY2030 supported by operational synergy realization
Terminal growth rate of 3.0% and terminal forward P/E multiple of 15.0x supported by 7.14% WACC

Bull20%

Price target

$109.99

+77.3% from spot

In the Bull scenario, Accession integration exceeds operational targets, delivering the upper bound of $1.8B in annual revenue and achieving $40M in cost synergies. Specialty Distribution maintains operating margins of approximately 35% as the rollout of over 180 casualty-driven programs successfully neutralizes catastrophe property rate declines. In Retail, non-discretionary corporate risk and persistent healthcare inflation (medical up 8-10%, pharmacy up over 10%) drive advisory demand, lifting Retail organic growth to the top of guided ranges. High cash flow conversion of 24% to 27% allows Brown & Brown to rapidly pay down debt from its $8.07B stack, prompting multiple expansion toward peer averages.

Accession annual revenue contribution achieves the upper end of guidance at $1.8B
Operational cost synergies reach the top of guided range at $40M in FY2026
Specialty Distribution organic growth accelerates to 4.0% supported by 180 new casualty programs
Valuation multiple re-rates toward peer forward P/E levels of 15.34x as debt is rapidly retired

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($82.40). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.5%	2.8%	3.0%	3.3%	3.5%
7.0%	$90.0	$92.9	$96.3	$100	$104
7.5%	$83.7	$86.0	$88.6	$91.5	$94.8
8.0%	$78.5	$80.3	$82.4	$84.7	$87.2
8.5%	$74.1	$75.6	$77.3	$79.1	$81.2
9.0%	$70.4	$71.7	$73.0	$74.5	$76.2

Scorecard

Published factor rows and weighted composite

Valuation7.5

Management8.5

Balance Sheet6.0

Profitability5.5

Revenue Growth9.0

Risk Assessment7.5

Competitive Moat7.5

Earnings Quality8.0

Capital Efficiency5.5

Weighted composite

7.2/10

Above average

Category	Score	Reading
Valuation	7.5
Management	8.5
Balance Sheet	6.0
Profitability	5.5
Revenue Growth	9.0
Risk Assessment	7.5
Competitive Moat	7.5
Earnings Quality	8.0
Capital Efficiency	5.5

Historia rekomendacji

Rekomendacja, którą nosiło opublikowane w danym miesiącu wydanie analizy. Rekomendacja porównuje cenę z dnia analizy z wartością godziwą; nie jest zapisem tego, czy ocena się sprawdziła.

Rok	sty	lut	mar	kwi	maj	cze	lip	sie	wrz	paź	lis	gru
2026

Brown & Brown, Inc. (BRO)

Our latest published analysis: BRO rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · BRO

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on BRO

Frequently asked questions

Historia rekomendacji